These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Drug information services in Nepal: the changing perspectives. Chhetri AK; Palaian S; Mishra P Kathmandu Univ Med J (KUMJ); 2008; 6(1):117-21. PubMed ID: 18604128 [No Abstract] [Full Text] [Related]
6. [Drug committees are not necessary--therapeutic recommendations are issued anyway]. Jönsson B Lakartidningen; 2005 Jul 11-24; 102(28-29):2085-6: discussion 290-2. PubMed ID: 16097181 [No Abstract] [Full Text] [Related]
7. Content and accuracy of abstracting services: clinical perspective. Michel DJ Hosp Formul; 1988 Jul; 23(7):596-8, 601-3, 607. PubMed ID: 10288149 [TBL] [Abstract][Full Text] [Related]
8. [The right drug to the right patient in a right dosage is the goal of clinical pharmacology]. Lindell B Lakartidningen; 1984 May; 81(19):1931-43. PubMed ID: 6727471 [No Abstract] [Full Text] [Related]
9. [Reply 1: LAKSAK supports wise drug therapy using knowledge and sharp IT-tools]. Gustafsson LL; Hensjö LO Lakartidningen; 2000 Sep; 97(39):4347. PubMed ID: 11076480 [No Abstract] [Full Text] [Related]
10. Pharmacy newsletters: time for a new approach. Mitchell JF Hosp Formul; 1985 Mar; 20(3):360, 363-5. PubMed ID: 10270308 [TBL] [Abstract][Full Text] [Related]
11. Analysis of drug reports for the P&T Committee. Longe RL; Cross GW; Riley MW Hosp Formul; 1978 Mar; 13(3):228-9. PubMed ID: 10306915 [No Abstract] [Full Text] [Related]
12. [Letter: The role of the National Board of Health and Welfare in drug information]. Liljestrand A; Rosén A Lakartidningen; 1976; 73(20):1881-2. PubMed ID: 1271917 [No Abstract] [Full Text] [Related]
13. Guidelines for the provision of drug information services in hospitals. Can J Hosp Pharm; 1978; 31(5):185-7. PubMed ID: 10239059 [No Abstract] [Full Text] [Related]
14. [Role of drug information]. Lunde PK Tidsskr Nor Laegeforen; 1977 Jan; 97(3):150-1. PubMed ID: 835120 [No Abstract] [Full Text] [Related]
15. [Future drug committees--institutions for cooperation and information]. Odeberg H; Lenhoff K Lakartidningen; 1989 Jan; 86(1-2):34. PubMed ID: 2911227 [No Abstract] [Full Text] [Related]
16. Adverse drug effects: evaluation of four secondary reference sources. Lyon RA Hosp Formul; 1985 Mar; 20(3):315-7, 320-1. PubMed ID: 10270307 [TBL] [Abstract][Full Text] [Related]
17. A systematic approach to writing P&T drug reports. Longe RL Hosp Formul; 1978 Feb; 13(2):128-9. PubMed ID: 10306341 [No Abstract] [Full Text] [Related]
18. [Inspra and the drug benefits board: What is the role of the drug committees?]. Hoffmann M; Dahlqvist R; Levin LA; Silfverhielm B; Skoglund I; Vinge E Lakartidningen; 2005 Jul 11-24; 102(28-29):2088, 2090; discussion 290-2. PubMed ID: 16097183 [No Abstract] [Full Text] [Related]
19. [LFN's evaluation of Inspra illustrates the need of drug committees!]. Malmström R; Hjemdahl P Lakartidningen; 2005 May 30-Jun 5; 102(22):1751-2. PubMed ID: 15987055 [No Abstract] [Full Text] [Related]
20. [Swedish drug information of international interest]. Osterberg S Lakartidningen; 1975 Jun; 72(26):2743. PubMed ID: 1142909 [No Abstract] [Full Text] [Related] [Next] [New Search]